Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Rhea-AI Summary

Mural Oncology plc (Nasdaq: MURA) has announced its first Virtual Investor Day, scheduled for September 26, 2024, at 10 a.m. ET. The event will provide clinical insights and updates on the company's late-stage candidate, nemvaleukin alfa, an engineered IL-2 therapy. Mural remains on track to deliver key data readouts from potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025.

The Investor Day will feature presentations from Mural's leadership, including CEO Caroline Loew and CMO Vicki Goodman, as well as expert clinicians. They will discuss the trial design, clinical proof of concept, and unmet needs in target cancer types. Additionally, Mural will provide an overview of its IL-18 pipeline program.

The event aims to showcase Mural's progress in developing novel, engineered cytokine therapies for various cancers. Interested parties can register for the webcast at ir.muraloncology.com/events-and-presentations.

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program

Clinicians to share expert perspectives around the potential of new cytokine-based immunotherapies

Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025

WALTHAM, Mass. and DUBLIN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that it will host a virtual Investor Day on Thursday, September 26, 2024, beginning at 10 a.m. ET.

Mural leadership, including Caroline Loew, Ph.D., CEO, and Vicki Goodman, MD, Chief Medical Officer, will provide new clinical insight into the trial design and assumptions of the company’s late-stage and potentially registrational trials of nemvaleukin, an engineered IL-2. Those trials are on track to deliver topline results in 1H 2025. Mural will also provide an overview and data presentation of its IL-18 program.

The Investor Day will also feature clinician discussion as follows:

• Clinical proof of concept of Mural’s lead program, nemvaleukin: Ulka Viashampayan, MD, Professor, Internal Medicine, Division of Hematology/Oncology, University of Michigan
  
  
• Unmet need in platinum-resistant ovarian cancer: John Hays, MD, PhD, an associate professor in the Divisions of Medical Oncology and Gynecologic Oncology, and member of the Translational Therapeutics Program at The Ohio State University Comprehensive Cancer Center
  
  
• Mucosal melanoma and need for dedicated treatments: Rich Carvajal, MD, Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute
  

The event will conclude with a live Question & Answer section.

Register to attend the Investor Day webcast at ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.

About Nemvaleukin
Nemvaleukin alfa (nemvaleukin) is a novel, engineered cytokine designed to leverage antitumor effects of the IL-2 pathway while mitigating the hallmark toxicities that limit its use. Nemvaleukin selectively binds to the intermediate-affinity IL-2 receptor (IL-2R) and is sterically occluded from binding to the high-affinity IL-2R. Because of this molecular design, nemvaleukin treatment leads to preferential expansion of antitumor CD8+ T cells and natural killer cells, with minimal expansion of immunosuppressive regulatory T cells. Nemvaleukin is currently being evaluated in two potentially registrational late-stage trials.

About Mural Oncology’s IL-18 Program
IL-18 is a potent immune-stimulating cytokine, but its efficacy is blunted by IL-18 binding protein (IL-18BP), a high affinity decoy receptor that binds to, and neutralizes, IL-18, thereby rendering it ineffective. Native IL-18’s potency is also limited by its short half-life. Mural Oncology’s novel approach to protein engineering is designed to mitigate these issues. First, Mural introduced mutations to IL-18 that eliminate binding to IL-18BP while minimally impacting the native IL-18 structure. Second, it fused IL-18 to protein scaffolds which extend the half-life and increase IL-18’s exposure. Together, these have demonstrated more durable immunological effect in preclinical studies. Mural intends to nominate a development candidate for its IL-18 program by the end of this year.

About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential, and reach, of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the company’s pipeline and development programs, including the expected timing of clinical updates from the ARTISTRY-6 and ARTISTRY-7 trials, the expected timing of preclinical updates and candidate selection, including with respect to the Company’s IL-18 program, the potential of the company’s product candidates and programs to address unmet medical needs, and the continued progress of its pipeline and programs. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, the inherent risks and uncertainties associated with competitive developments, preclinical development, clinical trials, recruitment of patients, product development activities and regulatory approval requirements; that preclinical or interim results and data from ongoing clinical studies of the company’s cytokine programs and product candidates may not be predictive of future or final results from such studies, results of future clinical studies or real-world results; future clinical trials or future stages of ongoing clinical trials may not be initiated or completed on time or at all; the company’s product candidates, including nemvaleukin, could be shown to be unsafe or ineffective; changes in the cost, scope and duration of development activities; the U.S. Food and Drug Administration may make adverse decisions regarding the company’s product candidates; and those other risks and uncertainties set forth in the company’s filings with the Securities and Exchange Commission (“SEC”), including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 and in subsequent filings the company may make with the SEC. All forward-looking statements contained in this press release speak only as of the date of this press release. The company anticipates that subsequent events and developments will cause its views to change. However, the company undertakes no obligation to update such forward-looking statements to reflect events that occur or circumstances that exist after the date of this press release, except as required by law.

Contact:
Katie Sullivan
katie.sullivan@muraloncology.com

FAQ

When is Mural Oncology (MURA) hosting its Virtual Investor Day?

Mural Oncology (MURA) is hosting its Virtual Investor Day on September 26, 2024, starting at 10 a.m. ET.

What is the main focus of Mural Oncology's (MURA) Investor Day presentation?

The main focus is on providing clinical insights and updates on nemvaleukin alfa, Mural's late-stage candidate, and an overview of their IL-18 pipeline program.

When does Mural Oncology (MURA) expect to deliver key data readouts for nemvaleukin trials?

Mural Oncology (MURA) expects to deliver key data readouts from potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in the first half of 2025.

Who are some of the expert clinicians presenting at Mural Oncology's (MURA) Investor Day?

Expert clinicians presenting include Dr. Ulka Viashampayan from the University of Michigan, Dr. John Hays from The Ohio State University, and Dr. Rich Carvajal from the Northwell Health Cancer Institute.

What types of cancer is Mural Oncology (MURA) targeting with nemvaleukin alfa?

Mural Oncology (MURA) is targeting platinum-resistant ovarian cancer and mucosal melanoma with nemvaleukin alfa in its potentially registrational trials.